

---

<b>Product name:</b>	CBL Rabbit Monoclonal antibody
<b>Cat number:</b>	MABN01771
<b>Conjugate:</b>	Unconjugated
<b>Size:</b>	100µL
<b>Clone:</b>	Monoclonal
<b>Concentration:</b>	1mg/ml
<b>Host:</b>	Rabbit
<b>Isotype:</b>	IgG
<b>Immunogen:</b>	A synthetic peptide of human CBL
<b>Reactivity:</b>	Human
<b>Applications:</b>	WB 1:500-1:1000, ICC/IF 1:50-1:200, IP 1:20-1:50
<b>Molecular Weight:</b>	Calculated MW: 100 kDa; Observed MW: 120 kDa
<b>Purification:</b>	Affinity Purified
<b>Form:</b>	Liquid
<b>Buffer:</b>	50mM Tris-Glycine(pH 7.4), 0.15M NaCl, 40% Glycerol, 0.01% Sodium azide and 0.05% BSA
<b>Storage:</b>	Store at 4°C short term. Aliquot and store at -20°C for 12 months. Avoid freeze/thaw cycles.
<b>Background:</b>	<p>This gene is a proto-oncogene that encodes a RING finger E3 ubiquitin ligase. The encoded protein is one of the enzymes required for targeting substrates for degradation by the proteasome. This protein mediates the transfer of ubiquitin from ubiquitin conjugating enzymes (E2) to specific substrates. This protein also contains an N-terminal phosphotyrosine binding domain that allows it to interact with numerous tyrosine-phosphorylated substrates and target them for proteasome degradation. As such it functions as a negative regulator of many signal transduction pathways. This gene has been found to be mutated or translocated in many cancers including acute myeloid leukaemia. Mutations in this gene are also the cause of Noonan syndrome-like disorder</p>